This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Anticholinergic drug use and risk for dementia: Target for dementia prevention


Jessen, Frank, Kaduszkiewicz, Hanna, Daerr, Moritz, Bickel, Horst, Pentzek, Michael, Riedel-Heller, Steffi, Wagner, Michael, Weyerer, Siegfried, Wiese, Birgitt, van den Bussche, Hendrik, Broich, Karl, Maier, Wolfgang


European Archives of Psychiatry and Clinical Neuroscience, Volume: 260, No.: Suppl 2, Pages.: S111-S115

Year of Publication



An increasing number of longitudinal cohort studies have identified a risk increase for dementia by the chronic use of drugs with anticholinergic properties. The respective data from the German Study on Aging, Cognition and Dementia in Primary Care Patients (AgeCoDe) also showing risk increase (hazard ratio = 2.081) are reported here. The mechanisms by which the risk increase is transported are still unknown. Irritation of compensated alterations of cholinergic transmission at the pre-dementia stage of Alzheimer’s disease (AD) or acceleration of neuroinflammation by disturbance of the anti-inflammatory effect of cholinergic innervation are discussed. In terms of dementia prevention, centrally acting anticholinergic drugs should be strictly avoided, because of long-term dementia risk increase in addition to acute negative effects on cognition. (PsycINFO Database Record (c) 2012 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{Jessen_2010, doi = {10.1007/s00406-010-0156-4}, url = {}, year = 2010, month = {oct}, publisher = {Springer Science $mathplus$ Business Media}, volume = {260}, number = {S2}, pages = {111--115}, author = {Frank Jessen and Hanna Kaduszkiewicz and Moritz Daerr and Horst Bickel and Michael Pentzek and Steffi Riedel-Heller and Michael Wagner and Siegfried Weyerer and Birgitt Wiese and Hendrik van den Bussche and Karl Broich and Wolfgang Maier}, title = {Anticholinergic drug use and risk for dementia: target for dementia prevention}, journal = {Eur Arch Psychiatry Clin Neurosci} }


anticholinergic, anticholinergic drug usage, cholinergic blocking drugs, dementia, dementia prevention, drugs, of, patients, prevention, risk factors, side effects drug, use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cohort Study

Type of Outcomes

Risk reduction (of dementia and co-morbidities)

Type of Interventions

Risk Factor Modification

Risk Factor Modifications

At risk population